Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Why Is Teva Stock Trading Higher On Tuesday?
Where Today's News Shapes Tomorrow
March 25, 2026
Headlines
